Updated hourlyHourly refreshMon, Oct 26, 2026
Press Release Database
Recent press releases, indexed by topic.
Finance · Crypto
Proprietary IP Position Until At Least 2042 to Enable Consolidation of Infrastructure targeting market expected to grow from $9.6 billion in 2025 to $93.4 billion in 2035
Customer Acquisition Plan Leverages Existing Relationship with NFL Alumni Health
Final Guidance issued by FDA Provides Roadmap for Prescription Drug Proprietary Health Lives Here™ App and DelivMeds® Software
Network of 6,500 Pharmacies to Provide Nationwide Physical Healthcare Outlet
Oct 22 · 11:40·Newswire.com
Automotive · Biotech & pharma
Oral presentation will feature preclinical research evaluating Tikva's armored allogeneic CD19 CAR T-cell therapy as a potential lymphodepletion-free approach for systemic lupus erythematosus SINGAPORE, Oct. 22, 2026 -- Tikva Allocell Pte. Ltd. ("Tikva"), a biotechnology...
Oct 22 · 11:03·PR Newswire
Finance · Healthcare
SAN DIEGO, Oct. 22, 2026 -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced a collaboration with Foundation Medicine, Inc. to develop a companion diagnostic assay (CDx) for the EGFR C797S resistance mutation. The collaboration will leverage the ongoing Phase 1/2 SOLARA clinical trial evaluating BH-30643 in the targeted treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) patients to validate the assay.
Oct 22 · 11:00·GlobeNewswire
Finance · Biotech & pharma
MALVERN, Pa., Oct. 22, 2026 -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, will host a conference call and live webcast on Wednesday, November 4, 2026, at 8:30 a.m. ET to provide a business update and report third quarter 2026 financial results. All related materials will be made available on the Ocugen investor website prior to the start of the call.
Oct 22 · 11:00·GlobeNewswire
Biotech & pharma · Medical devices
OKLAHOMA CITY, October 22, 2026--Antogen, Inc., a biotechnology company pioneering next-generation personalized diagnostics through immunopeptidomics, today announced that its new laboratory in Oklahoma City is fully operational and processing customer samples. This marks a significant milestone in Ant
Oct 22 · 11:00·Business Wire
Finance · Biotech & pharma
SILVER SPRING, M.D. & RESEARCH TRIANGLE PARK, N.C., October 22, 2026--United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announced today that the company's Board of Directors has authorized a new share repurchase program for up to $2 billion of the company's common stock, av
Oct 22 · 11:00·Business Wire
Finance · Healthcare
Dr. Luis Diaz, gastrointestinal oncologist and head of the Division of Solid Tumor Oncology at MSK, speaks at a recent Swim Across America - Long Island Sound open water swim. Drs. Andrea Cercek and Luis Diaz, along with a patient who is alive 10 years after participating in the initial clinical trial for Jemperli (dostarlimab), celebrate the funding from Swim Across America that made this clinical trial possible. Gr
Oct 22 · 10:30·EIN Presswire
Biotech & pharma
The Asthma Drugs Market is expanding as the prevalence of asthma increases and healthcare providers place greater emphasis on effective respiratory disease management. Asthma drugs are used to control airway inflammation, relieve breathing difficulties, and prevent acute asthma attacks. These ...
Read more
Oct 22 · 10:17·PR News Releaser
Finance · Healthcare
PURCHASE, N.Y., Oct. 22, 2026 — Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, has aligned with the U.S. Food and Drug Administration (FDA) on key elements of a Phase 3 study in dementia with Lewy bodies (DLB) including patient selection, dose, … Continue reading "Cognition Therapeutics Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (CT1812) in Dementia with Lewy Bodies"
Oct 22 · 10:15·PressReach
Healthcare · Food & drink
CureCMT Wearable sensors will track real-world changes in foot drop, walking, and hand function across four sites, a major step toward the first approved CMT treatment NEW YORK, NY, UNITED STATES, October 22, 2026 / EINPresswire.com / -- BioSensics LLC and CureCMT (Hereditary Neuropathy Foundation) today announced a two-year cooperative agreement award of up to $2.2 million from the U.S. Food and Drug Administration,
Oct 22 · 10:15·EIN Presswire
Finance · Biotech & pharma
SAN CARLOS, Calif., October 22, 2026--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its third quarter 2026 financial results on Thursday, November 5, 2026, before the financial markets open. Following the release of the financials, the Company will
Oct 22 · 10:01·Business Wire